Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.680
-0.030 (-1.75%)
At close: Mar 9, 2026, 4:00 PM EDT
1.650
-0.030 (-1.79%)
After-hours: Mar 9, 2026, 7:55 PM EDT
Lexicon Pharmaceuticals Revenue
In the year 2025, Lexicon Pharmaceuticals had annual revenue of $49.80M with 60.24% growth. Lexicon Pharmaceuticals had revenue of $5.49M in the quarter ending December 31, 2025, a decrease of -79.31%.
Revenue (ttm)
$49.80M
Revenue Growth
+60.24%
P/S Ratio
14.29
Revenue / Employee
$483,524
Employees
103
Market Cap
711.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 49.80M | 18.72M | 60.24% |
| Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| Gyre Therapeutics | 107.27M |
| Theravance Biopharma | 80.33M |
| Prime Medicine | 4.63M |
| ProKidney | 744.00K |
LXRX News
- 4 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - GlobeNewsWire
- 6 days ago - Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences - GlobeNewsWire
- 11 days ago - Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 - GlobeNewsWire
- 4 weeks ago - Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 5 weeks ago - Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 5 weeks ago - Lexicon Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary - GlobeNewsWire